Respiratory Distress Syndrome (e.g., Ards, Irds, Etc.) Affecting Patents (Class 514/1.5)
  • Patent number: 10711041
    Abstract: Cyclic peptide of formula I X1-GQRETPEGAEAKPWY-X2, wherein X1 comprises an amino acid (sequence), with 1 to 4 members, comprising natural and unnatural amino acids, and X2 comprises a natural amino acid, and wherein X1 comprises the N-terminal amino acid left in position 1, and X2 the C-terminal amino acid in the ultimate, right position, in the form of a lyophilisate without additives and/or stabilizers and its use.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: July 14, 2020
    Assignee: APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas
  • Patent number: 10632178
    Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 28, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami
  • Patent number: 10519197
    Abstract: The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A protein-reactive electrophilic group such as an epoxyketone, an aziridinylketone, or a beta-lactone is attached to the C-terminal amino acid. Upon contact with a proteasome complex in a target cell, the electrophilic group reacts with a functional group in or near a binding pocket or active site of the proteasome, forming a covalent bond and thereby inactivating the proteasome. These and other proteasome inhibitors can be screened for binding affinity and an ability to selectively eliminate senescent cells or cancer cells. Compounds that selectively remove senescent cells can be developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: December 31, 2019
    Assignee: Unity Biotechnology, Inc.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge
  • Patent number: 10353044
    Abstract: A system for determining a reconstruction of a particle distribution in an object based on electron paramagnetic resonance (EPR) measurement data of the object comprising the distribution of particles is described. The system comprises a data input for obtaining electron paramagnetic resonance measurement data of the object under study. The system also comprises a processor for processing the obtained data by applying a numerical model for solving a numerical inverse problem of deriving from the electron paramagnetic resonance measurement data a reconstruction of the particle distribution. The system furthermore comprises an output port for outputting data based on the derived reconstruction of the particle distribution.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: July 16, 2019
    Assignee: PEPRIC NV
    Inventors: Guillaume Crevecoeur, Annelies Coene, Luc Dupre, Peter Vaes
  • Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Patent number: 10221210
    Abstract: The present disclosure provides methods and compositions for separating polypeptide glycoforms using a medium that includes an Fc receptor. In certain embodiments, a medium includes an Fc receptor which comprises an extracellular portion of an Fc gamma RIII receptor.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: March 5, 2019
    Assignee: Zepteon, Incorporated
    Inventors: Glen Reed Bolton, Austin Wayne Boesch
  • Patent number: 9861649
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 9, 2018
    Assignee: National Jewish Health
    Inventor: Dennis R. Voelker
  • Patent number: 9844584
    Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis. Also disclosed are a pharmaceutical composition or a food composition containing the peptide as an active ingredient, a usage of the peptide for preventing or treating sepsis, and a kit comprising the peptide and instructions.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 19, 2017
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 9802985
    Abstract: What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer TX1EX2X3E where X1, X2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 31, 2017
    Assignee: APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
  • Patent number: 9345716
    Abstract: A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: May 24, 2016
    Assignee: INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY
    Inventors: Rinti Banerjee, Anubhav Kaviratna
  • Publication number: 20150147325
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150141322
    Abstract: The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 21, 2015
    Applicant: National University Corporation Okayama University
    Inventors: Masahiro Nishibori, Shuji Mori, Hidenori Wake, Hideo Takahashi, Keyue Liu, Kiyoshi Teshigawara, Masakiyo Sakaguchi
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Patent number: 9012403
    Abstract: The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: April 21, 2015
    Assignee: XiberScience GmbH
    Inventors: Peter Petzelbauer, Sonja Reingruber
  • Publication number: 20150099692
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMBAX CO., LTD., GEMVAX AS
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150099691
    Abstract: A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), wherein: the chiral centers in formula (I) are S and R configurations respectively; each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C1-C4 alkyl-substituted hydroxyl group, a C1-C4 alkoxyl group, a carboxylic acid group, a C1-C4 alkyl nitrile-substituted, C1-C4 alkyl-substituted or C1-C4 alkoxyl-substituted amido group, a C1-C4 alkyl-substituted ester group and a benzoyl group having a C1-C4 alkyl-substituted benzene ring; and each of RM and RS is selected from a group consisting of a hydrogen, a hydroxyl group, a phenyl group, a pyridinyl group, a carboxylic acid group, a C1-C4 alkoxyl substituted ester group, and a benzoyl group having a hydroxyl-substituted, a halogen-substituted, a C1-C4 alkoxyl-substituted or a C1-C4 alkyl-substituted benzene ring.
    Type: Application
    Filed: April 9, 2014
    Publication date: April 9, 2015
    Applicant: CHANG GUNG UNIVERSITY
    Inventors: Tsong-Long Hwang, Pei-Wen Hsieh, Yin-Ting Huang, Chih-Hao Hung
  • Publication number: 20150086618
    Abstract: The invention generally relates to compositions and methods for the reduction or neutralization of toxins associated with a bacterial, mycobacterial, fungal, viral, or protozoal agent. More particularly, the invention is directed to sterically stabilized phospholipid micellar and liposomal compositions, which interact with the toxins to decrease or neutralize their toxicity. Additionally, the invention includes the use of sterically stabilized phospholipid micellar compositions comprising one or more water-insoluble antibiotic, antifungal, antiviral, antiprotozoal, or anti-inflammatory agent(s), wherein the micellar or liposomal composition inhibits the formation of aggregates. The invention further includes the use of sterically stabilized micelle and liposomal compositions to deliver compounds to the site of action, and in some cases targets the compound to the site of action, for the treatment of inflammation and infection.
    Type: Application
    Filed: September 30, 2014
    Publication date: March 26, 2015
    Inventors: HAYAT ONYUKSEL, ISRAEL RUBENSTEIN
  • Publication number: 20150087576
    Abstract: The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a Serum Amyloid P (SAP) composition in an amount and for a time sufficient to suppress neutrophil movement into the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. Further, the disclosure relates to a method of increasing the number of neutrophils in a body region by administering an anti-SAP antibody or material able to bind SAP. The disclosure further relates to compositions usable with these methods.
    Type: Application
    Filed: December 13, 2012
    Publication date: March 26, 2015
    Inventors: Richard Gomer, Anu S. Maharjan, David J. Roife
  • Patent number: 8987223
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 24, 2015
    Assignee: Oncogenex Technologies Inc.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Publication number: 20150079094
    Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 19, 2015
    Inventors: Joyce Tombran-Tink, Colin J. Barnstable
  • Publication number: 20150079105
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Levels of CCL7 have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of CCL7 and/or other members of the PAR1-CCL7 axis, or CCL2 can be used to prevent and/or treat these conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicant: ucl Business PLC
    Inventors: Rachel Chambers, Paul Mercer, Andrew Williams
  • Patent number: 8980826
    Abstract: The present invention relates to a method of promoting bronchodilation by administration of streptolysin O to a subject in need thereof.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 17, 2015
    Assignee: Beech Tree Labs, Inc.
    Inventor: John McMichael
  • Publication number: 20150031599
    Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue or red blood cells with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
    Type: Application
    Filed: August 4, 2014
    Publication date: January 29, 2015
    Inventors: Abraham ABUCHOWSKI, Glenn Kazo, Friedericke Kazo, Ronald G. Jubin
  • Publication number: 20150011458
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Application
    Filed: June 17, 2014
    Publication date: January 8, 2015
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Publication number: 20150004165
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Patent number: 8921306
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The University of Queensland
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • Publication number: 20140364358
    Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
    Type: Application
    Filed: March 7, 2014
    Publication date: December 11, 2014
    Applicant: Apeptico Forschung UND Entwicklung GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas
  • Patent number: 8895500
    Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved binding affinity to the tumor necrosis factor.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: November 25, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
  • Publication number: 20140341876
    Abstract: Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a defensin polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD), are described. The polypeptide and/or NAD can be administered via inhalation. Also disclosed is a pharmaceutical composition including at least one defensin polypeptide and NAD. In vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide, are also described.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Joel Moss, Linda Stevens, Rodney L. Levine
  • Publication number: 20140322226
    Abstract: Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicant: QUESTCOR PHARMACEUTICALS, INC.
    Inventors: James KNIGHT, Steve CARTT, David YOUNG, Patrice BECKER
  • Publication number: 20140323390
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: July 9, 2014
    Publication date: October 30, 2014
    Applicant: IRM LLC
    Inventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
  • Publication number: 20140315786
    Abstract: The present invention relates to targeting an intracellular enzyme for release of covalently linked bioactives which results in a synergistic effect between the bioactives. The present invention relates to the use of bioactives that are directly connected covalently or through a covalent molecular linker which have increased therapeutic activity when released as the free bioactives by intracellular enzymes as compared to when the bioactives are administered individually (i.e. not covalently linked). Further, methods are described of administering to patients in need thereof, bioactives as linked bioactives having increased therapeutic activity. Accordingly, this invention also relates to methods of treating patients for certain diseases.
    Type: Application
    Filed: March 16, 2012
    Publication date: October 23, 2014
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventors: Michael R. Jirousek, Jill C. Milne, David Carney, Jean E. Bemis, Chi B. Vu
  • Patent number: 8865643
    Abstract: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: October 21, 2014
    Assignee: Medical Research Council
    Inventors: Howard Clark, Palaniyar Nadesalingam, Kenneth B. Reld, Peter Strong
  • Publication number: 20140296130
    Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventor: Amir Tamiz
  • Patent number: 8846607
    Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: September 30, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Jennifer Fiegel, Jean Sung
  • Publication number: 20140286906
    Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Daniel Bilbao Cortes, Nadia Rosenthal, Luisa Luciani
  • Publication number: 20140249072
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Application
    Filed: May 4, 2012
    Publication date: September 4, 2014
    Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
  • Patent number: 8822409
    Abstract: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: September 2, 2014
    Assignee: Phylogica Limited
    Inventors: Nadia Marian Dorothy Milech, Paul Michael Watt, Patrick G. Holt, Deborah Strickland
  • Patent number: 8785374
    Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 22, 2014
    Assignee: Alba Therapeutics Corporation
    Inventor: Amir Tamiz
  • Publication number: 20140194343
    Abstract: [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. [Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.
    Type: Application
    Filed: May 9, 2012
    Publication date: July 10, 2014
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Yoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
  • Patent number: 8754049
    Abstract: A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: June 17, 2014
    Assignee: APEPTICO Forschung und Entwicklung GmbH
    Inventors: Bernhard Fischer, Rudolf Lucas, Susan Tzotzos
  • Patent number: 8754037
    Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 17, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
  • Patent number: 8735343
    Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: May 27, 2014
    Assignee: National Jewish Health
    Inventor: Carl W. White
  • Publication number: 20140142021
    Abstract: The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein SP-C with analogues of the native surfactant protein SP-B. The invention is also directed to pharmaceutical compositions and kits thereof and to its use for the treatment or prophylaxis of RDS and other respiratory disorders.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A
    Inventors: JAN JOHANSSON, TORE CURSTEDT
  • Publication number: 20140127232
    Abstract: Provided herein are methods for preventing or treating bronchopulmonary dysplasia (BPD) in a subject. The methods comprise identifying connective tissue mast cells (CTMCs) in a subject and administering an agent that blocks an activity of blocks an increase in a level of or reduces a level of the CTMCs in the subject. Also provided are methods of identifying a subject with or at risk for developing BPD. Also provided are methods for determining the effectiveness of a treatment regime for BPD in a subject.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 8, 2014
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Thomas J. Mariani, Gloria S. Pryhuber
  • Patent number: 8715654
    Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: May 6, 2014
    Assignee: Celtaxsys, Inc.
    Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
  • Patent number: 8703697
    Abstract: A method for treatment of severe diffuse acute respiratory distress syndrome in an intubated-ventilated patient which includes sedating said patient with at least one alpha-2 agonist, maintaining spontaneous ventilation and applying pressure support ventilation of at least 5-10 cmH2O combined to a high positive end expiratory pressure (PEEP) of 10-24 cmH2O. A pharmaceutical composition containing at least one alpha-2 agonist suitable for treatment of ARDS in combination with, if appropriate, at least one sedative agent which does not depress ventilatory drive is also disclosed.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 22, 2014
    Inventor: Luc Quintin
  • Publication number: 20140094400
    Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.
    Type: Application
    Filed: November 22, 2011
    Publication date: April 3, 2014
    Applicant: LANTHIOPEP B.V.
    Inventors: Louwe De Vries, Sieger Adriaan Nelemans, Rick Rink, Antonius Jacobus Marinus Roks, Gert Nikolaas Moll
  • Patent number: 8673861
    Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: March 18, 2014
    Assignee: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman